Hormone replacement therapy by Hickey, M. et al.
 
PUBLISHED VERSION  
   
 
 
Hickey, Martha; Elliott, Caroline Jane; Davison, Sonia Louise  
Hormone replacement therapy British Medical Journal, 2012; 344:e763. 
© The Authors 
 























Thus authors may use their own articles for the following non commercial purposes without asking 
our permission (and subject only to acknowledging first publication in the BMJ and giving a full 
reference or web link, as appropriate). 
•  Posting a pdf of their own article on their own personal or institutional website for which no 





rd November 2012 THERAPEUTICS
Hormone replacement therapy
Martha Hickey professor of obstetrics and gynaecology
1, Jane Elliott senior lecturer
2, Sonia Louise
Davison senior postdoctoral research fellow
3
1University of Melbourne, The Royal Women’s Hospital and the University of Melbourne, Melbourne, VIC3052, Australia;
2University of Adelaide,
Discipline of Obstetrics & Gynaecology, School of Paediatrics and Reproductive Health, Adelaide, SA5005, Australia;
3Monash University, Women’s
Health Research Program, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, The Alfred
Centre, 99 Commercial Road, Melbourne, VIC3004, Australia
This is one of a series of occasional articles on therapeutics for common
or serious conditions, covering new drugs and old drugs with important
new indications or concerns. The series advisers are Robin Ferner,
honorary professor of clinical pharmacology, University of Birmingham
and Birmingham City Hospital, and Philip Routledge, professor of clinical
pharmacology, Cardiff University. To suggest a topic for this series,
please email us at practice@bmj.com.
A 51 year old woman presents to her general practitioner with
troublesome hot flushes and night sweats for the past eight
months. She is sexually active and her last period was about 5
months ago. She has taken a number of over-the-counter
preparations,butnonehavebeeneffective.Sheisanxiousabout
havinghotflushesatworkandexhaustedfromsleepdisturbance.
She wants advice about managing her symptoms.
What is hormone replacement therapy?
Menopauseisanormalphysiologicaleventinwomen,occurring
at a median age of 51 years. Hormone replacement therapy
(HRT)containsoestrogenforrelievingmenopausalsymptoms;
for women who still have their uterus it is combined with a
progestogen for endometrial protection. The oestrogen
(oestradiol, oestradiol 17β, oestrone, or conjugated equine
oestrogen) can be oral, intravaginal, or transdermal. The
progestogen can be oral, transdermal, or delivered via an
intrauterinedevice(Mirena,BayerSchering).InHRTregimens
the oestrogen is taken daily, with progestogen added either
sequentially (cyclic regimen) or daily (continuous combined
regimen) if it is needed.
1 Tibolone is an oral synthetic steroid
preparation with oestrogenic, androgenic, and progestogenic
actionsthatcanalsobeusedasHRT.Testosteronecanbeadded
to HRT, but the role of supplemental testosterone will not be
covered in this case.
The key indication for HRT or tibolone is the presence of
troublesomevasomotorsymptoms(hotflushesandnightsweats,
with or without awakening). Vasomotor symptoms are normal
andaffectabout80%ofwomenduringthemenopausetransition
and are severe in about 20% of these women. The duration of
these symptoms varies, with a median of four years, but may
continueforasmanyas12yearsinabout10%ofwomen.
2HRT
may be indicated when menopausal symptoms are adversely
affecting quality of life.
How well does HRT work?
HRT is currently the most effective treatment for troublesome
vasomotorsymptoms.Asystematicreviewshowedasignificant
mean reduction in the frequency of hot flushes by around 18 a
week and in the severity of hot flushes by 87% compared with
placebo.
3 Large randomised controlled trials have confirmed
that HRT also significantly reduces fracture risk, improves
vaginal dryness and sexual function, and may also improve
sleep,muscleachesandpains,andqualityoflifeinsymptomatic
women.
4 5 The figure⇓ provides the estimated absolute benefits
from HRT use in postmenopausal women aged 50-59 years or
<10 years after menopause, based on background risk in
American women,
6 using data from the largest randomised
controlled trial of HRT versus placebo to date (the Women’s
Health Initiative study)
4 and the prospective observational
Nurses’ Health Study.
6 7 HRT (oestrogen alone and combined)
showssignificantabsolutebenefitforthetreatmentofvasomotor
symptoms, vaginal dryness, and fracture reduction and for the
prevention of diabetes.
The relative efficacy of tibolone compared with conventional
HRTisnotwellestablished.Onelarge,multicentrerandomised
double blind controlled trial found that tibolone reduced hot
flushes as much as low dose (1 mg) oral oestradiol in
postmenopausalwomenaged45-65years.Tibolonecausedless
bleeding in the first three months of treatment and less breast
tenderness
8 and may also improve sexual function.
9
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Practice
PRACTICEClinical indications for HRT
Current evidence based guidelines
6 10-12 advise consideration of
HRT for troublesome vasomotor symptoms in perimenopausal
and early postmenopausal women without contraindications
and after individualised discussion of likely risks and benefits.
Starting HRT in women over age 60 years is generally not
recommended. For women with premature (age <40 years) or
early (<45 years) menopause, current guidelines recommend
HRT until aged 50 for the treatment of vasomotor symptoms
andbonepreservation.HRTreducesfracturerisk,butincreased
risk of osteoporosis alone is not an indication for HRT.
Similarly, although HRT may also improve mood and libido,
these are not primary indications for treatment. Vaginal
symptoms alone do not require systemic HRT and can be
managed with local oestrogens.
How safe is HRT?
For most symptomatic women, use of HRT for ≤5 years is safe
and effective. HRT is contraindicated in some women and may
leadtoadverseoutcomesinothers.Therearecurrentlynolarge
randomised controlled trials of the benefits and harms of HRT
in women around the normal age of menopause (50-59 years),
whichiswhenvasomotorsymptomsaremosttroublesome.The
figure⇓ shows the estimated risks associated with HRT use in
postmenopausal women aged 50-59 years or <10 years after
menopause. However, these data are derived largely from the
subgroup aged 50-59 years in the Women’s Health Initiative
Study
4 and the Nurses’ Health Study.
7 The background risk of
most adverse events linked with HRT increases with age, and
risks will differ according to age and current health status.
Furthermore, the Women’s Health Initiative study used a
regimen of oral conjugated oestrogen (Premarin) (with or
without medroxyprogesterone acetate) versus placebo, and it is
uncertainwhetherotherpreparationsanddeliverysystemshave
similar effects. The principal risks of HRT to consider are
thromboembolic disease (venous thromboembolism and
pulmonary embolism); stroke; cardiovascular disease; breast
and endometrial cancer; and gallbladder disease.




13 These risks increase with age and with
other risk factors, such as obesity, previous thromboembolic
disease, smoking, and immobility. In younger (<60 years)
healthy women the absolute risk of thromboembolic disease is
lowandmortalityrisksfromvenousthromboembolismarelow.
The type, dose, and delivery system of both oestrogen and
progestogen may influence the risk of thromboembolic
disease—for example, a recent systematic review found that
oral but not transdermal HRT increased the risk of venous
thromboembolism.
13Inalargeprospectiveobservationalstudy,
low dose (≤1.5 mg oral, or ≤50 μg transdermal) oestradiol did
not increase the incidence of venous thromboembolism in low
risk populations.
14 In clinical practice, previous venous
thromboembolism and high risk of venous thromboembolism
are contraindications for HRT. If HRT is used by women at
increased risk of thromboembolic disease, a transdermal
preparation and reduced oestrogen dose are preferred. In the
absence of personal or family history, screening for inherited






may be lower with transdermal HRT at doses of 50 μg or less,
17
but this has not been shown in randomised controlled trials. In
older women (>65 years) tibolone increases the risk of stroke.
18
In clinical practice avoid HRT or tibolone in women at high
risk of stroke.
HRT and cardiovascular disease
The relation between HRT and cardiovascular disease is
controversial, but the timing and duration of HRT, as well as
pre-existingcardiovasculardisease,arelikelytoaffectoutcomes.
In the estimated risks for younger women (aged 50-59 years)
(figure⇓), there was no statistically significant cardiovascular
riskorharmforHRT.HRTisgenerallyavoidedinolderwomen
(>60), who are more likely to have established cardiovascular
disease. Subgroup analysis from larger trials suggests that
starting HRT in younger postmenopausal women may have a
favourable effect on cardiovascular health,
19 but the validity of
this“timinghypothesis”hasnotyetbeenshownbyappropriately
designed studies. In those who start HRT at about age 50 years
andcontinuebeyondage60yearsthecardiovascularrisksfrom
HRT are unknown.
HRT and breast cancer
Combined HRT
CombinedHRT(oestrogenplusprogestogen)increasestherisk
of a breast cancer diagnosis or breast cancer mortality.
20 The
risk of breast cancer with tibolone is not established, but large
observationalstudiessuggestanincreasedrisk.
21TheWomen’s
Health Initiative study reported an excess breast cancer risk
attributable to combined HRT of 8 per 10 000 women a year
after four to five years of use. This equates to about a 0.1%
increaseinbreastcancer.
4CombinedHRTalsoincreasesbreast
density and the risk of having an abnormal mammogram.
22
Oestrogen-only HRT
Data are conflicting over the risk of breast cancer with
oestrogen-only HRT. In the Women’s Health Initiative study,
conjugated equine oestrogen (Premarin) did not increase the
risk of breast cancer for up to seven years of use in women who
had had a hysterectomy.
11 18 Most observational studies report
no increased risk for up to five years of use,
6 but the large,




cancer with combined HRT than with oestrogen alone.
HRT and endometrial cancer
Inwomenwhohaveanintactuterus,unopposedoestrogenmay
lead to endometrial hyperplasia and increases the risk of
endometrial cancer.
1 For this reason women who retain their
uterus and use oestrogen should also take progestogen.
Combined continuous HRT does not increase the risk of
endometrial cancer provided that adequate duration and dose
ofprogestogenareused,butsequentialHRTmayincreaserisk.
1
Tibolone does not increase the risk of endometrial hyperplasia
or cancer.
23
HRT and gallbladder disease
Large randomised controlled trials have shown that HRT
increases the risk of cholecystitis. Observational data (the
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PRACTICEMillion Women Study) show that this risk may be reduced by
using transdermal rather than oral HRT, avoiding one
cholecystectomy in every 140 users.
24
What are the precautions for HRT?
No consensus has been reached on absolute contraindications
to HRT. However, on the basis of the above data, we advise
avoiding or discontinuing HRT in patients with the following:
• A history of breast cancer, as HRT may increase the risk
of breast cancer recurrence and of new breast cancers.
25
Tibolone also increases the risk of breast cancer
recurrence.
26 Exclude breast disease and investigate any
abnormalities before starting HRT. Counsel women
considering HRT that it may increase their risk of an
abnormal mammogram and that combined HRT may
increase their risk of breast cancer after four to five years
of use
• Apersonalhistoryorknownhighriskofvenousorarterial
thromboembolic disease, including stroke and
cardiovascular disease, as HRT may further increase risk.
Tibolone increases stroke risk in older women.
18 If HRT
is prescribed, a transdermal preparation with minimal
oestrogenispreferred.Intheabsenceofpersonalorfamily
history, screening for inherited thrombophilias is not
indicated before starting HRT
15
• Uncontrolled hypertension.
Other conditions that require caution with use of HRT include:
• Abnormal vaginal bleeding. HRT should not be started in
women with undiagnosed abnormal vaginal bleeding.
Combined HRT may often cause unscheduled bleeding in
the first six months of use. Persistent or new onset (after
six months) unscheduled bleeding on HRT requires
investigation to exclude pelvic disease
• Abnormal liver function. Avoid oral HRT products since
these are metabolised in the liver
• Migraine. This does not seem to be exacerbated by HRT
so migraine is not a contraindication, but low dose
transdermal preparations may be preferable
27
• History of endometrial or ovarian cancer. Seek specialist
review before considering HRT
• High risk of gallbladder disease. Advise that HRT may
increase this risk further, although the risk may be lower
with transdermal therapy.
How cost effective is HRT?
HRTisprincipallyatreatmentformenopausalsymptoms,which
makescosteffectivenessdifficulttomeasure.Modellingstudies
of quality of life years (QALYs) gained in the United Kingdom
and the US have used data from the Women’s Health Initiative
studyandconsideredfracturereduction,breastcancer,colorectal
cancer, coronary heart disease, stroke, and venous
thromboembolic events over five years of HRT use.
25 28 They
show that HRT is cost effective in all women compared with
no treatment but that the cost effectiveness was greater in those
with more severe vasomotor symptoms (UK data, estimated
cost per QALY gained: £580 (€700; $920) for women with an
intact uterus and £205 for women who had had a
hysterectomy).
28 However, this model did not include the cost
of investigating abnormal uterine bleeding with HRT or
additional abnormal mammograms.
How is HRT taken and monitored?
Before HRT is started
• Consider HRT in perimenopausal or recently
postmenopausalsymptomaticwomenwithlowriskfactors
for cardiovascular or thromboembolic disease.
• Considerthenatureandseverityofmenopausalsymptoms
and their impact on function and quality of life, the
woman’s age and health status, as well as her wishes for
treatment.
• Itisreasonabletoadviseyounger,healthypostmenopausal
women that HRT is unlikely to increase their risk of
cardiovascular disease. However, HRT is not currently
indicated in women at any age for preventing or treating
cardiovascular disease.
6 10-12
• Discuss with women any modifiable risk factors for
cardiovascular disease, such as alcohol, smoking, diabetes
and hypertension control. Avoid prescribing HRT in
womenwithestablishedcardiovascularorcerebrovascular
disease or at high risk of these conditions. Calculate





• Consider HRT in those at high risk of fracture if there are
nocontraindications.Calculatefractureriskusinganonline
tool such as FRAX (www.shef.ac.uk/FRAX) and measure
bone density with bone densitometry.
• Consider whether anxiety and/or depression may be
contributing to the symptom burden.
29 Somatic symptoms
ofmenopause,suchaspalpitationsandsleepdisorder,may
be difficult to distinguish from those of depression and
anxiety. HRT may reduce palpitations and improve sleep
and may improve mood but is not a treatment for clinical
anxiety or depression.
• Individualise discussion of risk and benefit; written
informationishelpful.Discussotherpossiblemanagement
options (see “Tips for patients” box).
• Ensure breast and cervical screening are up to date and
investigate any abnormal vaginal bleeding.
Starting HRT
• Available HRT preparations vary between countries and
regions. In the UK see the British National Formulary
(bnf.org/bnf/bnf/current/100039.htm) and in Australasia





• Use the lowest effective dose of HRT for the minimum





without contraindications, combined oral contraceptive
preparations will treat vasomotor symptoms and reduce
fracture risk.
• No clear consensus has emerged on whether oral or
transdermal therapy is first line, but transdermal may be
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PRACTICEpreferable in those with risk factors for thromboembolic
disease or if oral absorption may be limited.
• Oestrogen alone should be used in women after
hysterectomy. The progestogen component of HRT may
be progesterone or a progestogen, which binds to the
progesterone receptor. Observational studies suggest that
HRT products containing a micronised progesterone or
dydrogesterone may be associated with a lower risk of
breastcancer,cardiovasculardisease,andthromboembolic
events, but adequately powered randomised controlled
trials have not yet been conducted.
• In perimenopausal women consider cyclic HRT or (in
women under 50 years) low dose combined oral
contraceptives to minimise irregular bleeding. In women
whoareonetotwoyearspostmenopausalandwishtoavoid
bleeding, consider continuous combined HRT or tibolone.
• Ensure that you discuss the patient’s expectations of
effectiveness. Some women are happy to achieve a lower
level of symptom reduction to minimise side effects or
hormone exposure.
• Tailor the dosage and type of HRT to symptoms and
possible side effects. Start with a low dose oestrogen and
consider gradually increasing the dose after four to six
weeks if troublesome vasomotor symptoms persist.
Monitoring HRT
• Monitoreffectivenessbyimprovementinsymptoms(blood
tests are rarely useful).
• Mastalgia and irregular bleeding may respond to a
reduction in oestrogen dose.
• Unscheduled bleeding in the first six months of HRT use
does not need investigation, but investigate new onset or
persistent bleeding to exclude pelvic disease (www.sign.
ac.uk/pdf/qrg61.pdf).
• Ifvasomotorsymptomspersistdespiteadequateabsorption
of oestradiol, investigate other causes of hot flushes or
sweating.
• Review patients at least annually to evaluate indications
for use, assess individuals’ risk and benefit profile, and
promotelifestyleinterventionstoreduceorpreventchronic
disease.
6 10-12 HRT does not cause weight gain.
• The schedule for other screening tests such as
mammography and cervical smears is not altered by HRT
use.
Continuing or ceasing HRT
Base the decision on whether to advise continuation of HRT on
symptoms and ongoing risks and benefits rather than a set
minimum or maximum duration of therapy. Cessation of HRT
leadstorecurrentsymptomsforupto50%ofwomen.Consider
the potential impact of recurrent symptoms on quality of life.
The risks of HRT may be related to duration of HRT use—for
example, the risk of venous thromboembolism is greatest in the
first year of use, but the risk of breast cancer increases with
duration of use. Most guidelines recommend using HRT for up
to four to five years. No clear consensus has emerged on how
to discontinue HRT, and symptoms may recur regardless of
whether HRT is stopped slowly or suddenly.
What are the alternatives to HRT for
menopausal symptoms?
For hot flushes and night sweats
• HRTiscurrentlythemosteffectivetreatmentforvasomotor
symptoms.
• Effective non-hormonal preparations include
serotonin-norepinephrine reuptake inhibitors (venlafaxine
and desvenlafaxine) and selective serotonin reuptake
inhibitors (paroxetine, fluoxetine, citalopram, and
escitalopram).
31
• Selective serotonin reuptake inhibitors that induce
CYP2D6, particularly paroxetine and fluoxetine, should
be avoided in women who take tamoxifen as they may
interfere with the metabolism of tamoxifen.
32
• Gabapentin is the only non-hormonal product shown to be
equally effective as low dose oestrogen for vasomotor
symptoms.
33 34
• Clonidine is mildly effective.
31
• Relaxation therapy, mindfulness based therapies, and
cognitive behaviour therapy may improve vasomotor
symptoms.
31 35Arecentsystematicreviewshowednoeffect
for any other interventions (including acupuncture,
homeopathy, vitamin E, or magnetic devices) for hot
flushes after breast cancer.
31
• Overall, data from large randomised controlled trials do
not support the efficacy of black cohosh or other “natural
remedies” for the treatment of hot flushes.
36
• So called “bio-identical” hormones have not been shown
to be safe or effective.
6
For atrophic vaginitis
• Vaginal dryness can be effectively treated with topical
oestrogen.
37 Vaginal oestrogens can be used safely in the
long term without additional progestogens.
38
• Non-hormonal options for atrophic vaginitis include
lubricants and vaginal moisturisers, although there is little
evidence to suggest they offer the sustained benefit
associated with vaginal oestrogen.
9
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PRACTICETips for patients
• Hormone replacement therapy (or HRT) contains oestrogen to treat menopausal symptoms and, for women who have not had a
hysterectomy, a progestogen to protect the uterus from cancer. Its risks and benefits have been extensively studied. HRT is a safe
and effective treatment for most healthy women with symptoms who are going through the menopause at the average age (about 51
years)
• Risks and benefits of HRT will vary according to age and other health problems. Discuss with your doctor your potential risks and
benefits from HRT, whether it is suitable for you, and if so, which product may be best
• HRT is the most effective treatment in reducing the number and severity of hot flushes and night sweats at menopause. It may also
improve sleep, joint aches and pains, and vaginal dryness. HRT protects against fractures resulting from osteoporosis
• HRT is also recommended when menopause occurs in women younger than 45 years until aged 50 who do not have any other
conditions that might mean HRT is not suitable for them
• The effects of tibolone are similar to those of HRT, but less is known about the risks and benefits of tibolone
• Other effective treatments for hot flushes and night sweats include some antidepressants and gabapentin, a drug also used for chronic
pain
• Relaxation, meditation, and cognitive behavioural therapy may also be helpful
• When vaginal dryness is the main problem, only vaginal oestrogen has been proved effective, but vaginal lubricants and moisturisers
may also be helpful
• Discuss with your doctor your expectations of treatment. Higher doses of HRT may be more effective in reducing symptoms of hot
flushes but may also confer greater risk. Using the lowest dose for the shortest effective time is the current approach to treatment
• Discuss ongoing use of HRT yearly with your doctor. HRT does not change the usual frequency of cervical smears and mammogram
screening
Patient consent not required (patient anonymised, dead, or hypothetical).
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Estimated benefits and risks of oral HRT in postmenopausal women aged 50-59 years, or <10 years after menopause.
Panel B shows more clearly the data in the lower part of panel A. Asterisks indicate statistically significant hazard ratios
(P<0.05)
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